Tigulixostat Appears Promising for the Treatment of Gout

Treatment-emergent adverse events were comparable across all groups, with no serious events reported during the study. Three severe treatment-emergent adverse events, all of which resolved or resolved with sequelae, did occur but were deemed to be unrelated to treatment with tigulixostat.

Treatment with tigulixostat at all three doses appeared effective and well tolerated. These results and the observed safety profile support tigulixostat dose finding and the continued development of this agent for patients with gout and hyperuricemia.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

Terkeltaub R, Mune J, Lee J, et al. Phase 2 study results from a randomized, double-blind, placebo-controlled, dose-finding study to evaluate efficacy and safety of tigulixostat, a novel non-purine selective xanthine oxidase inhibitor, in gout patients with hyperuricemia [abstract: L05]. Arthritis Rheumatol. 2021 Oct; 73(suppl 10).

The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…

In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.

When uric acid becomes elevated in the human body, a variety of problems can develop, most notably gout—a painful, inflammatory arthritis caused by uric acid crystal deposition in joints. Chronically elevated uric acid can also lead to painful kidney stones. The majority of patients found to have hyperuricemia, however, never go on to develop gout…

New research explores association between hyperurecimia and gout with metabolic derangement

Reference

Research Roundup: Abstract Data Presented at ACR Convergence 2021

Tigulixostat Promising for Patients with Gout & Hyperuricemia

Treating Asymptomatic Hyperuricemia Could Lower Risk of Developing Chronic Conditions

Gout, Glucose Metabolism and Obesity: A Case Review

Reference

Related Articles